Eagle Genomics, a trailblazer in microbiome-related research software, has successfully secured an additional £3 million (approximately USD $4 million) in funding. This latest financial boost, backed by existing investors such as Environmental Technologies Fund, abrdn plc, and a consortium led by Granpool Innovative Investments, aims to further the deployment of the company's groundbreaking software platform. The new funding elevates Eagle Genomics' total capital raised to over £20 million (USD $25 million) in the past year.
New Leadership Appointments & Changes
In conjunction with the fundraising, Eagle Genomics is thrilled to announce significant changes in its leadership team. Dr. Victoria Kimonides has been appointed as the new CEO and Board Member of the company. With nearly 14 years of leadership experience at Microsoft, Dr. Kimonides brings a wealth of knowledge in technology strategy and partner relations. She holds a BSc in Biochemistry and Microbiology from King's College London and a PhD from the University of Cambridge in Neuroscience. Dr. Kimonides is also a Fellow of the Cambridge Judge Business School.
Additionally, John Schoellerman joins the Board as its Chair. Currently serving as SVP, Corporate & Business Development at Oxford Nanopore Technologies plc, Schoellerman has been pivotal in private financing and long-term strategy development. He was previously a Managing Director and Head of the Medical Technology practice at Lazard, a leading global investment bank.
Alongside these appointments, Anthony Finbow will transition to a new role as Chief Evangelist. In this capacity, he will focus on helping the company reach its full potential and advocate for the exploration of the Microbiome and innovative breakthroughs in the field. The company also acknowledged the contributions of Cliff Meltzer, who will be retiring from the Board.
Conclusion
The additional funding and leadership changes mark a significant milestone for Eagle Genomics as it continues to pioneer in the realm of microbiome research. With a fortified leadership team and financial backing, the company is well-positioned to accelerate its global expansion and contribute meaningfully to sustainable agriculture and healthcare sectors. The appointments of Dr. Victoria Kimonides and John Schoellerman, coupled with Anthony Finbow's new role, underscore the company's commitment to innovation and excellence in microbiome research.